• Lupin inks strategic pact with Enzene Biosciences to launch Cetuximab in India. • Cetuximab is the first biosimilar for head and neck cancer treatment.
• Net profit came at Rs 287 cr vs loss of Rs 118 cr YoY. • Revenue was up 16.9% YoY at Rs 2,491 cr. • EBITDA was up 30% YoY at Rs 727 cr. • Margin came at 29.2% vs 26.3% YoY.
• Net profit was down 38.2% YoY at Rs 17.3 cr. • Revenue was up 22.7% YoY at Rs 284.7 cr. • EBITDA was up 57.4% YoY at Rs 60 cr. • Margin came at 21% vs 16.4% YoY.
Swipe Up
Check More Details